SRP product and index pages do not print CAS, UNII, PubChem CID, molecular formula, sequence, termini (free acid vs amide), salt form, or a public COA. Identity below is taken only from opened public registries and from primary papers that name Semax / Met-Glu-His-Phe-Pro-Gly-Pro / ACTH(4–7)PGP.

Opened SRP 10 mg product page (16 August 2026): title “Semax 10 mg Neuroscience Research Peptide Vial”. Category: Brain & Mind Research. Subhead: Semax (10 mg Vial) — COA verified research compound. For laboratory research use only. Not for human consumption. Also “Semax (10 mg / 3 mL Vial).” Also known as: ACTH(4-10) Analog. Bullets: 10 mg lyophilized research compound in a 3 mL research vial; COA available for batch verification; high-purity research material; intended for qualified laboratory and analytical research; securely packaged; For Research Use Only. Not for human or veterinary use. Description: supplied for controlled laboratory evaluation of Semax within Brain & Mind Research studies. Footer: for laboratory research only; not for human or animal use, consumption, administration, diagnosis, treatment, or therapeutic application. Availability: 4 in stock (can be backordered). Price was not printed on the opened product-page markdown. Product URL: http://simpleresearchpeptides.com/product/semax-10-mg-vial/.

Not printed on the opened product page and therefore not claimed as SRP-verified: MEHFPGP sequence; free acid vs amide termini; CAS; UNII; CID; salt/counter-ion; a public COA file; a published laboratory dose.

Opened SRP index card (compound-research-guides, 16 August 2026): “Semax (10 mg Vial)” under Cognitive; tagged Evidence profile. Overview: Semax is a synthetic ACTH(4-7)-derived heptapeptide studied in neuroprotection, cognition, and stress-related signaling. That index sentence is vendor/index copy, not a nootropic treatment claim. Mechanism: reported effects involve neurotrophic signaling, neurotransmitter systems, and gene expression without the classic adrenal steroidogenic activity of full ACTH. Evidence: clinical and preclinical publications exist, but much of the human evidence is regionally concentrated and not broadly replicated in large modern trials. Quality note: do not generalize from ACTH or other melanocortin fragments. Confirm the exact Semax sequence. Last editorial review on that index: August 2026.

Opened dedicated-guide URLs http://simpleresearchpeptides.com/research-compound-directory/semax-research/ and .../semax-research-guide/ returned HTTP 404. This page is written for that missing guide.

Catalog “Brain & Mind / nootropic / neuroprotection” language does not convert a research heptapeptide into ACTH, an approved stroke drug, or Selank. This page does not make nootropic treatment claims.

Semax is not intact ACTH. Opened index language and Dolotov 2006 (PMID 16996037) describe an ACTH(4–10) analog without assigning classic adrenal steroidogenesis to the heptapeptide. Do not cite ACTH replacement or cortisol literature as Semax evidence.

Semax is not Selank. Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro (CID 11765600), a tuftsin analog. They share a C-terminal Pro-Gly-Pro and appear together in Kost et al. 2001 (PMID 11443939) as separate inhibitors of human-serum enkephalin-degrading enzymes (opened IC50: Semax 10 µM; Selank 20 µM). Shared enzyme-assay data are not identity.

Do not equate this vial with ACTH, ACTH(4–10) MEHFRWG, Selank, melanotan, or an FDA-approved nootropic or stroke drug. Research use only.

Opened primary papers support an ACTH-fragment / glyproline working model with effects on hippocampal BDNF/trkB, ischemia-associated gene/protein expression in rats, and in-vitro serum enkephalinase inhibition. It is not a treatment claim. It was not generated with an SRP 10 mg vial. Observed means a measurement in an opened paper. Proposed means a hypothesis. Not shown means the opened papers did not establish it for a research-market lot.

Observed — resting-state fMRI in healthy volunteers (historical / small). Lebedeva et al. 2018 (PMID 30225715): resting-state fMRI in healthy volunteers (11 men and 13 women; mean age printed 43.9±9.5 years); Semax n=14 vs placebo n=10; scans before and 5 and 20 min after the paper’s intranasal 1% Semax session (study condition). Default-mode-network topography change reported. Panikratova et al. 2020 (PMID 32342318): resting-state functional connectivity in 52 healthy participants after Selank or Semax, with amygdala and DLPFC ROIs. These are opened small imaging reports. They are not Phase 3 packages, not FDA evidence, and not proof an SRP lyophilized vial reproduces those sessions. They are not nootropic treatment claims.

Not shown for an SRP 10 mg vial. Not shown on an opened page: a completed cell-surface receptor assignment; human PK of a research-market lot; proof that the SRP lot is CID 9811102 free acid; BDNF / ischemia data generated with that lot; a US ClinicalTrials.gov Semax administration record; FDA approval.

Label every row. Semax ≠ ACTH ≠ Selank. Historical “nootropic / stroke” language is not a completed therapeutic program and is not an instruction.

Read the “what it did not show” column. Published study designs are historical facts from those papers. They are not a protocol. Cell-culture micromolar concentrations, rodent µg/kg figures, and “intranasal 1%” imaging sessions are study conditions, not instructions for an SRP 10 mg research vial.

Human / NCT snapshot. No opened Semax administration NCT on ClinicalTrials.gov (term and intervention queries both 0). Do not invent one.

These are gaps. Treating any of them as settled is incorrect.

Each card is a single opened record. Historical human language is not a protocol. Micromolar IC50 values, rodent µg/kg figures, and imaging-session conditions are study conditions, not instructions.

Semax is an investigational laboratory research heptapeptide. It is not an FDA-approved drug for human use. This page is educational. It does not provide dosing, reconstitution, administration, or any human-use instructions. The 10 mg mass is a vendor listing, not a published laboratory protocol.

Simple Research Peptides (SRP) materials are for laboratory research only and are not for human or veterinary use, consumption, administration, diagnosis, treatment, or therapeutic application.

Laboratory identity is the first practical issue. Opened registries describe Semax as CID 9811102 / CAS 80714-61-0 / UNII I5FAL2585H / H-MEHFPGP-OH. SRP product pages do not print sequence, CAS, UNII, termini, salt, or a public COA. A method written for ACTH, ACTH(4–10) MEHFRWG, Selank, or an approved neurologic drug is not automatically valid for this vial.

Confirm peptide identity, termini (free acid vs amide), stereochemistry, salt, and purity by LC-MS before treating a vial as the literature article. Independently sourced research peptides are not established as equivalent to Dolotov 2006 or Lebedeva 2018 material. Historical rodent schedules, micromolar enzyme IC50 values, and imaging-session conditions are study conditions from those papers. They are not a reconstitution scheme.

No reconstitution scheme, no administration route, and no human or veterinary use protocol appears on this page. Research use only.

Sources actually opened for this draft. Do not add PMIDs or NCTs that are not on the allowed list.

Allowed PMID list used on this page: 11443939, 16996037, 32580520, 34201112, 33418449, 30225715, 32342318. No administration NCT.

Product links are research materials, not treatment recommendations. Opened SRP page: Semax 10 mg Neuroscience Research Peptide Vial; AKA ACTH(4-10) Analog; Brain & Mind Research. Footer: for laboratory research only; not for human or animal use, consumption, administration, diagnosis, treatment, or therapeutic application. Sequence, CAS, UNII, termini, salt, and a public COA were not printed. Do not confuse with ACTH, native ACTH(4–10) MEHFRWG, Selank 10 mg (CID 11765600 / TKPRPGP), or an approved neurologic drug.